Regulatory News:
BioAlliance Pharma (Paris:BIO) :
Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):
Date | Total number of outstanding shares | Total number of voting rights | ||
December 31, 2011 | 17,659,715 |
Theoretical number of voting rights: 17,659,715
Number of real voting rights: 17,644,235 |
About BioAlliance Pharma
Dedicated to Specialty Pharma and
Orphan products in cancer treatment and in supportive care, with a focus
on drug resistance, BioAlliance conceives and develops innovative
products, for specialty markets especially in the hospital setting and
for orphan or rare diseases.
Created in 1997 and introduced to the
Euronext Paris market in 2005, BioAlliance Pharma's ambition is to
become a leading player in these fields by coupling innovation to
patient needs. The company's teams have the key competencies required to
identify, develop and register drugs in Europe and USA; the products'
commercialization rights are licensed to international commercial
partners invested in the hospital setting. In areas where medical needs
are insufficiently met, its targeted approaches help overcome drug
resistance and improve patient health & quality of life. For more
information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.
BioAlliance Pharma SA
Judith Gréciet, CEO
Tel.:
+33 1 45 58 76 01
Judith.greciet@bioalliancepharma.com
or
Nicolas
Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE
RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com